Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA tentatively agrees to include Parsol 1789 in sunscreen monograph at feedback meeting.

This article was originally published in The Tan Sheet

Executive Summary

FDA "TENTATIVELY" AGREES TO INCLUDE PARSOL 1789 3% IN SUNSCREEN MONOGRAPH, FDA Office of OTC Drug Evaluation Director Michael Weintraub, MD, said at an Aug. 11 "OTC feedback" meeting on Givaudan-Roure's sunscreen ingredient Parsol 1789 (avobenzone). "We tentatively believe that 3% or less Parsol 1789 is safe and effective and can be included in the monograph," Weintraub stated. FDA's May 1993 tentative final monograph on sunscreens did not include Parsol 1789.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084161

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel